Lobbying

Minorities for Medical Marijuana's latest lobbying report covers Q1 2024, at $8,250. Its first report covers Q4 2022; the issues it reports most are Banking and Economics/Economic Development.

Minorities for Medical Marijuana

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Minorities for Medical Marijuana lobbying by quarter
Minorities for Medical Marijuana lobbying by quarter
QuarterAmountReports
Q4 2022$8,0001
Q1 2023$8,2501
Q2 2023$8,2501
Q3 2023$8,2501
Q4 2023$8,2501
Q1 2024$8,2501
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Banking$9,850 · 6 reports
  • Economic development$9,850 · 6 reports
  • Government issues$9,850 · 6 reports
  • Medical research and clinical labs$9,850 · 6 reports
  • Small business$9,850 · 6 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Agriculture, Dept of (USDA)6 reports
  • Bureau of Indian Affairs (BIA)6 reports
  • Commerce, Dept of (DOC)6 reports
  • HOUSE OF REPRESENTATIVES6 reports
  • Interior, Dept of (DOI)6 reports
  • Minority Business Development Agency6 reports
  • SENATE6 reports
  • Treasury, Dept of6 reports

Firms it paid

Firm
Banks & Company$49.3K6 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
24/05/07for Q1 2024Banks & Company$8,250
24/02/05for Q4 2023Banks & Company$8,250
23/10/23for Q3 2023Banks & Company$8,250
23/07/24for Q2 2023Banks & Company$8,250
23/05/01for Q1 2023Banks & Company$8,250
23/01/27for Q4 2022Banks & Company$8,000